39 Results for "

HNSCC

" in MedChemExpress (MCE) Product Catalog:
Products (39)

39 Results for "HNSCC" in MCE Product Catalog:

17
17 Publications Verification
Cat. No.: HY-13241A
CAS No.: 862505-00-8
Synonyms: LY2228820
Target:  

p38 MAPK Autophagy

Research Areas:  

Cancer

Ralimetinib is an ATP-competitive p38α and p38β MAPK inhibitor with an IC50 of 5.3 nmol/L against human p38α and an IC50 of 3.2 nmol/L against human p38β. Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer, ovarian cancer, glioma, multiple myeloma, breast cancer, renal cancer, and head and neck squamous cell carcinoma .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-136173
CAS No.: 1801765-04-7
Purity:  99.41%
Synonyms: TNO155
Target:  

SHP2 Phosphatase

Research Areas:  

Cancer

Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P99032
CAS No.: 1228763-95-8
Synonyms: IPH2201
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-19896
CAS No.: 1039455-84-9
Target:  

MDM-2/p53 Apoptosis

Research Areas:  

Cancer

COTI-2, an anti-cancer agent with low toxicity, is an orally available third generation activator of p53 mutant forms. COTI-2 acts both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. COTI-2 induces apoptosis in multiple human tumor cell lines. COTI-2 exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. COTI-2 converts mutant p53 to wild-type conformation .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1607
CAS No.: 1414-45-5
Target:  

Bacterial Antibiotic

Research Areas:  

Infection Inflammation/Immunology

Nisin is a bacteriocin produced by a group of Gram-positive bacteria that belongs to Lactococcus and Streptococcus species. Nisin has antibacterial and anti-inflammatory activity .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15673
CAS No.: 1374996-60-7
Purity:  99.75%
KP372-1 is an Akt inhibitor that inhibits proliferation and induces apoptosis and anoikis. KP372-1 is also an NQO1 redox cycling agent that causes DNA damage (including DNA breakage) by generating ROS. KP372-1 can be used in cancer research (such as head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-117548
CAS No.: 1350549-36-8
Purity:  98.92%
UNC1062 is a highly selective tyrosine kinase (MERTK) inhibitor with an IC50 of 1.1 nM (Morrison Ki = 0.33 nM). UNC1062 exhibits good selectivity for the TAM family (TYRO3 IC50 = 60 nM, AXL IC50 = 85 nM). UNC1062 exhibits significant anti-proliferative effects and induces apoptosis in various cancer models (such as melanoma, gastric cancer, and acute myeloid leukemia). UNC1062 inhibits multiple pathways, including MAPK/ERK, PI3K/AKT and JAK/STAT and affects the motility of head and neck squamous cell carcinoma (HNSCC) cells through the RhoA signaling pathway. UNC1062 inhibits macrophage efferocytosis, and it suitable for research on atherosclerosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-134545
CAS No.: 401941-73-9
Purity:  ≥99.0%
Synonyms: NALA
Research Areas:  

Cancer

N-Arachidonoyl-L-alanine is an endocannabinoid analog with anti-cancer effects. N- Arachidonoyl-L-alanine kills HNSCC cells through 5-LO-mediated ROS productio .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-149913
CAS No.: 374101-64-1
Purity:  99.83%
Research Areas:  

Cancer

NR2F1 agonist 1, a nuclear receptor NR2F1 agonist, specifically activates dormancy programs in malignant cells. NR2F1 agonist 1 up-regulates NR2F1 and downstream target genes that regulate dormancy. NR2F1 agonist 1 induces neural crest-like and growth suppression in head and neck squamous cell carcinoma (HNSCC) via NR2F1 activation. NR2F1 agonist 1 inhibits tumor growth in a mouse primary tumor model .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-110077
CAS No.: 36707-00-3
Purity:  99.62%
Target:  

Akt Apoptosis Caspase PARP

Research Areas:  

Cancer

API-1 is a potent selective Akt/PKB inhibitor that reduces the level of phosphorylated Akt (IC50 = 0.8 μM). API-1 binds to the PH domain and inhibits Akt membrane translocation. API-1 induces c-FLIP degradation. API-1 reduces cell proliferation and induces apoptosis. API-1 decreases tumor growth in mouse xenograft model .
loading...
    loading...
Cat. No.: HY-P99406
CAS No.: 2213450-26-9
Synonyms: MCLA 158

Target:  

EGFR

Research Areas:  

Cancer

Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .
loading...
    loading...
Cat. No.: HY-177439
Research Areas:  

Cancer

HLX43 is an antibody-drug conjugate (ADC) targeting PD-L1. HLX43 consists of a human monoclonal antibody anti-PD-L1 antibody Opucolimab (HY-P99785) with the drug-linker conjugate being DL-01 (HY-155870A). HLX43 exerts superior anticancer efficacy with safety profile in vivo. HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research .
loading...
    loading...
Cat. No.: HY-171124
Synonyms: AZD9592
Tilatamig samrotecan (AZD9592) is an anti-EGFR/c-MET antibody-drug conjugate (ADC). Tilatamig samrotecan consists of an anti-EGFR/c-MET antibody with the drug-linker conjugate being AZ14170133 (HY-145399) (a topoisomerase I (TOP1i) inhibitor payload). Tilatamig samrotecan induces multiple DNA damage response pathway markers (like ATM, ATR, γH2AX). Tilatamig samrotecan selectively binds to EGFR and c-MET, delivering the cytotoxic payload. Tilatamig samrotecan exerts anti-tumor activity in vivo. Tilatamig samrotecan can be used for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) research .
loading...
    loading...
Cat. No.: HY-B1433
CAS No.: 95153-31-4
Synonyms: S 9780
Perindoprilat (S 9780) is an angiotensin-converting enzyme (ACE) inhibitor with the IC50 value ranging from 1.5 to 3.2 nM. Perindoprilat can be used in hypertension research .
loading...
    loading...
Cat. No.: HY-P99785
CAS No.: 2251771-79-4
Synonyms: HLX20; HLX43 antibody

Research Areas:  

Cancer

Opucolimab (HLX20) is an engineered anti-PD-L1 humanised IgG1 antibody. Opucolimab, when conjugated with camptothecin toxoid, yields the PD-L1-targeting ADC, HLX43 (HY-177439). HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research .
loading...
    loading...
Cat. No.: HY-P99406A

Target:  

EGFR

Research Areas:  

Cancer

Petosemtamab (FUT8-KO) is an anti-EGFR and anti-LGR5 monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucosyl loss enhances the ADCC effect of the antibody. Petosemtamab (FUT8-KO) leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab (FUT8-KO) can be used for research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC) .
loading...
    loading...
Cat. No.: HY-P99196
CAS No.: 1174900-84-5

Target:  

c-Met/HGFR

Research Areas:  

Cancer

Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
loading...
    loading...
Cat. No.: HY-P99141

Target:  

LAG-3

Research Areas:  

Inflammation/Immunology Cancer

Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4 + T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC) .
loading...
    loading...
Cat. No.: HY-P990947
CAS No.: 2868265-50-1
Synonyms: AZD9592 Antibody

Target:  

ADC Antibodies EGFR

Research Areas:  

Cancer

Tilatamig (AZD9592 Antibody) is a human antibody of the Ig (G1-κ_G1-λ2) subtype that targets EGFR/MET. Tilatamig conjugates with the Top1 inhibitor AZ14170133 (HY-145399) to form the antibody-drug conjugate (ADC) Tilatamig samrotecan (HY-171124) (AZD9592). Tilatamig accurately targets NSCLC models including EGFR-mutant, EGFR-wildtype, and EGFR tyrosine kinase inhibitor-treated ones, and its activity correlates with high expression of EGFR, c-MET and SLFN11. Tilatamig is available for in vivo anti-tumor studies in patient-derived xenograft models of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) .
loading...
    loading...
Cat. No.: HY-P99685
CAS No.: 1622327-37-0
Synonyms: IMGN-289; J2898A-SMCC-DM1

Research Areas:  

Cancer

Laprituximab emtansine (IMGN-289) is an immunotoxin targeting HER1. Laprituximab emtansine is an EGFR antibody-drug conjugate (ADC) consisting of the J2898A antibody, DM1 (anti-microtubule agent) and the SMCC thioether linker. Laprituximab emtansine can be used for cancer research .
loading...
    loading...